Importantly, the senolysis induction by GLS1i is specific to senescent cells and potentially less toxic as we observed no cell death was induced in melanocytes and no body weight loss was noted in an in vivo experiment after the treatment of the combination of CDK4/6i and GLS1, different from other senolytic drugs such as bcl-2/BCL-XL inhibitor Navitoclax that induces thrombocytopenia in clinical trials[47–49], making it challenging to combine navitoclax with other therapies like chemotherapy. Here, BCL2L1 is linked to Thrombocytopenia.